Phase 4 N=20 MIDCAB (Mid-Calf Block) for Foot Surgery
Ankle Surgery · Foot Surgery
Primary: Block Duration — 18.2 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Eating Chocolate at the Right Time Benefits the Circadiam Sytem and Metabolic Efficiency.
Menopause
Primary: Resting Energy Expenditure (Indirect Calorimetry) — 1249.33; 1377.67; 1360.40; 1468.50 kcal/day
N/A N=50 Effect of Combined Red and Near Infrared Light-emitting Diode (LED) Therapy on Tissue Regeneration Post Laser Treatment
Wound Heal
Primary: Days to Healing — 24; 24; 1; 0 participants
Phase 3 N=61 Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY
HIV
Primary: Bacterial Gene Richness (Observed Unique Genes). Analysis of the Composition, Structure and Function of the Intestinal Microbiome. * — 768358; 730732; 767756; 808911…
Phase 2 N=15 A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD
Mild Cognitive Impairment · Mild Dementia · Moderate Dementia
Primary: Blood Biomarkers of Pharmacodynamic Response- Cytokines — 26.672; 190.829; 20.309; 2293.879 picogram/milliliter (pg/ml)
N/A N=203 Optimizing the Previs Device for Prediction of Postoperative Ileus
Ileus
Primary: Device Sensitivity for Predicting Ileus. — 12; 2; 22; 39 Participants
Phase 3 N=1,085 A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Multiple Myeloma
Primary: Post-Consolidation Stringent Complete Response (sCR) Rate — 110; 157 Participants — p=0.0010
N/A N=189 R3 Delta Ceramic Acetabular System PAS U.S.
Degenerative Joint Disease
Primary: Overall Study Success at 3 Years Postoperative — 100; 13 Participants
N/A N=309 Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit
Chromium Deficiency · Diabetes Mellitus · Hyperlipidemias
Primary: Serum Chromium Level — 8.93; 9.74; 9.68; 11.01 µg/L
N/A N=20 Susceptibility of Cardiorespiratory Responses to Ozone During Cycling Exercise
Ozone Exposure During Rest and Exercise
Primary: Time-to-exhaustion on Maximal Cycling Bout — 209; 235 seconds — p=0.092
Phase 1 N=36 A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
Healthy · Hepatic Impairment
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib — 898; 1170; 732; 952 nanogram per milliliter (ng/mL) — p=0.3601
Phase 2 N=45 Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
GLUT1DS1 · Epilepsy · Glut1 Deficiency Syndrome 1, Autosomal Recessive
Primary: Neuropsychological Score of Sustained Attention — 11 Participants
Phase 4 N=108 Procedural Discomfort Related to Number of Intradetrusor Botox Injections
Overactive Bladder
Primary: Participant Discomfort Related to BTX-A Injection — 3.2; 3.6 score on a scale — p=0.21
Phase 2 N=53 Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
ADHD · Attention Deficit Disorder
Primary: Change in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms — 37.4; 37.3; 29.6; 29.0 units on a scale — p=0.7145
N/A N=203 ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation
Chronic Low-back Pain
Primary: Change in Oswestry Disability Index (ODI) — -19.7; -2.9 units on a scale — p=<0.001